Alma Bio Therapeutics

Alma Bio Therapeutics and Delphi Genetics extend strategic alliance on plasmid DNA drugs

Partnership will advance development of drugs aimed at treating underlying cause of uncontrolled inflammation in autoimmune diseases Alma Bio Therapeutics SAS (Alma) and Delphi Genetics SA announce today that they are taking their strategic alliance...
Invent Farma

Invent Farma of Neuraxpharm Group announces the acquisition of FB Health in Italy

The Invent Farma / neuraxpharm Group (the Group), a leading speciality generics company focussed on CNS, today announced the acquisition of FB Health S.p.A. (FB Health), an Italy-based speciality pharma company focused on neurology...
domainex

Domainex expands partnership with Imperial College London to reduce heart muscle damage during heart...

Domainex Ltd. expands its partnership with Imperial College London, to discover novel therapies that reduce heart muscle damage during heart attacks. The aim is to discover a drug that inhibits the enzyme MAP4K4, which plays...
Biocon mylan

Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s...

Bengaluru, Karnataka, India and HERTFORDSHIRE, England, PITTSBURGH, June 10/11, 2017 – Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of new data from the insulin...
biocon academy website screenshot

Biocon Academy Introduces First Of Its Kind Career Advancement Program In ‘Clinical Development’ in...

Bengaluru, Karnataka, India, June 08, 2017: Biocon Academy, a CSR initiative of Asia’s leading biotechnology company, has announced the introduction of a unique program in ‘Clinical Development’ in collaboration with Keck Graduate Institute (KGI) in...
Vaxon biotech

Vaxon announces results of its Phase IIb lung cancer trial of Vx-001

Paris, France, June 1, 2017 – Vaxon, a biopharmaceutical company developing therapeutic cancer vaccines based on optimized cryptic peptides, announces the results of its Phase IIb trial of Vx-001 in non-small-cell lung cancer (NSCLC)....
imcyse

Imcyse obtains authorization to launch Phase 1b trial in Type 1 diabetes

Liège, Belgium, May 30, 2017 – Imcyse, who develop active specific therapies for the treatment and prevention of severe chronic diseases, today announces that the Belgian and British regulatory authorities have authorized the launch...
medicen

Medicen Paris Region announces 20% business growth in 2016

Paris, May 18, 2017 – Medicen Paris Region, Europe’s leading healthcare cluster, today announces its review of business for the previous year. The 20% growth in activity was reflected in the budget increase, from...
Robocath

Robocath raises €4.7 million ($5.2M) to market its first medical robotic platform, R-one™, in...

Robocath, a medical robotics start-up that designs and develops innovative solutions for the treatment of cardiovascular diseases, today announces the conclusion of a new round of fundraising worth €4.7 million ($5.2M). This round was...
ATUM

ATUM Licenses Gene Design Software to Thermo Fisher Scientific

ATUM (formerly DNA2.0, Inc.) announced today that the company has signed a patent licensing agreement that gives Thermo Fisher Scientific access to the company’s novel gene design platform. "Most people think visually, so seeing a...